Serum CXCL1 concentrations are elevated in type 1 diabetes mellitus, possibly reflecting activity of anti-islet autoimmune activity

Diabetes/Metabolism Research and Reviews

Volumn 27, Issue 8, 2011, Pages 830-833

  Takahashi, Kazuma ^a   Ohara, Mio ^a   Sasai, Takayoshi ^a   Homma, Hiroyuki ^a   Nagasawa, Kan ^a   Takahashi, Toru ^a   Yamashina, Mitsuhiro ^a   Ishii, Mototsugu ^a   Fujiwara, Fumikado ^a   Kajiwara, Takashi ^a   Taneichi, Haruhito ^a   Takebe, Noriko ^a   Satoh, Jo ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

Chemokines; CXCL1; Dendritic cells; Human; Type 1 diabetes mellitus

Indexed keywords

C PEPTIDE; CXCL1 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; HEMOGLOBIN A1C; MONOCYTE CHEMOTACTIC PROTEIN 3;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DENDRITIC CELL; DISEASE COURSE; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; INSULIN DEPENDENT DIABETES MELLITUS; JAPANESE; MALE; MICROARRAY ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

ADOLESCENT; ADULT; AGED; C-PEPTIDE; CHEMOKINE CXCL1; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 80855131202     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.1257     Document Type: Article

References (11)

1. Verge CF, Stenger D, Bonifacio E, et al. Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: Combinatorial Islet Autoantibody Workshop. Diabetes 1998; 47(12): 1857-66.
2. Takahashi K, Oka Y, Satoh J. Lowered expressions of the NF-kB family members in dendritic cells from NOD mice are associated with a reduced expression of GATA-2. Ann N Y Acad Sci 2008; 1150: 59-60.
3. Wang X, Jia S, Geoffrey R, Alemzadeh R, Ghosh S, Hessner MJ. Identification of a molecular signature in human type 1 diabetes mellitus using serum and functional genomics. J Immunol 2008; 180(3): 1929-1937.
4. Collins CD, Purohit S, Podolsky RH, et al. The application of genomic and proteomic technologies in predictive, preventive and personalized medicine. Vascul Pharmacol 2006; 45(5): 258-267.
5. Kobayashi T, Tamemoto K, Nakanishi K, et al. Immunogenetic and clinical characterization of slowly progressive IDDM. Diabetes Care 1993; 16(5): 780-788.
6. Matos M, Park R, Mathis D, Benoist C. Progression to islet destruction in a cyclophosphamide-induced transgenic model: a microarray overview. Diabetes 2004; 53(9): 2310-2321.
7. Glabinski AR, Tuohy VK, Ransohoff RM. Expression of chemokines RANTES, MIP-1alpha and GRO-alpha correlates with inflammation in acute experimental autoimmune encephalomyelitis. Neuroimmunomodulation 1998; 5(3-4): 166-171.
8. De Paepe B, Creus KK, De Bleecker JL. Chemokine profile of different inflammatory myopathies reflects humoral versus cytotoxic immune responses. Ann N Y Acad Sci 2007; 1109: 441-453.
9. Torikai E, Kageyama Y, Suzuki M, Ichikawa T, Nagano A. The effect of infliximab on chemokines in patients with rheumatoid arthritis. Clin Rheumatol 2007; 26(7): 1088-1093.
10. Chen K, Wei Y, Alter A, Sharp GC, Braley-Mullen H. Chemokine expression during development of fibrosis versus resolution in a murine model of granulomatous experimental autoimmune thyroiditis. J Leukoc Biol 2005; 78(3): 716-724.
11. Engeman T, Gorbachev AV, Kish DD, Fairchild RL. The intensity of neutrophil infiltration controls the number of antigen-primed CD8 T cells recruited into cutaneous antigen challenge sites. J Leukoc Biol 2004; 76(5): 941-949.